AXGN compared with NPCE: revenue, margins and what each company keeps, and the suppliers and customers both name

AXGNAxogen, Inc.

Mkt capRevenueRevenue

NPCENeuroPace Inc

Mkt capRevenueRevenue

Compare

AXGNAxogen, Inc.

NPCENeuroPace Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

AXGN: latest quarter not drawable. NPCE: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

AXGN, solidNPCE, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AXGN 3

—Evergenunlistedsupplier

—University of Florida Research Foundation (UFRF)unlistedsupplier

—University of Texas at Austin (UTA)unlistedsupplier

Shared 0

No shared counterparties.

Only NPCE 4

—DIXI Medical USAunlistedsupplier

GBCIGreatbatchsupplier

—Micro Systems Technologies Managementunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Rapport Therapeutics

unlistedcustomer

AXGNAxogen, Inc.

49.37▼−0.52%· post 49.37

Mkt cap$2.9BRevenue$76MQ3 FY26Revenue$225MFY25

NPCENeuroPace Inc

12.28▼−5.61%· post 12.28

ClosedOct 30 '26

Mkt cap$422.2MRevenue$23MQ2 FY26Revenue$96MFY25

Compare

ClosedOct 30 '26

AXGNAxogen, Inc.

NPCENeuroPace Inc

49.37▼−0.52%post 49.37

Price

12.28▼−5.61%post 12.28

$2.9B

Mkt cap

$422.2M

Q3 FY26$76M

Revenue

$23MQ2 FY26

FY25$225M

Revenue

$96MFY25

AXGN49.37▼−0.52%vsNPCE12.28▼−5.61%ClosedOct 30 '26